Background: The World Health Organization proposes that elimination of onchocerciasis transmission (EOT) be verified in 12 endemic countries by 2030. In sub-Saharan Africa (SSA), where most cases occur, Niger is the only country that has been verified to date. Despite decades of ivermectin mass drug administration (MDA), infection persists in West and Central Africa. Alternative treatment strategies (ATS) are necessary to accelerate progress towards EOT by 2030 and beyond. Methods: We used the EPIONCHO-IBM transmission model to project the number of years, from 2026, to reduce microfilarial (mf) prevalence below 1% across 1,634 implementation units (IUs) in 19 SSA countries. We fitted the model to geostatistically-derived mf prevalence in 1975, 2000 and 2018, and projected mf prevalence through to 2025. We classified IUs according to their baseline endemicity, intervention history programmatic performance, and current (2025) MDA frequency (annual or biannual). For those IUs that would not reach < 1% mf prevalence by 2030 if current strategies were continued, we simulated ATS (increasing treatment frequency, improving coverage, and adopting moxidectin MDA) from 2026 to 2040. Results: Of the 1,486 IUs currently under annual ivermectin MDA, 45% would require ATS. In those low-moderate endemicity IUs, biannual ivermectin would have a comparable impact to that of switching to annual moxidectin; in those with high endemicity, adopting biannual moxidectin would be more impactful. Of the 148 IUs currently receiving biannual ivermectin, 24% would benefit from ATS, switching to biannual moxidectin being the best option. Conclusion: This work brings into sharper focus which IU profiles are most likely to require ATS across SSA. In highly-endemic IUs with long intervention histories, biannual moxidectin MDA may be required under our modelling assumptions, with substantial uncertainty surrounding the permanent sterilising effect, of the two drugs under comparison, upon adult female worms. National programmes aiming to reach EOT will have options that need to be balanced against financial considerations. Implementation studies will also be important for translating these modelling projections into national policy decisions, particularly where different intervention strategies generate similar epidemiological benefits. Economic and epidemiological evaluations of repeated moxidectin MDA are needed to inform these decisions.